MDGL Overview
Upcoming Projects (MDGL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MDGL)
-
A second look: Checking in with a prescriber of Madrigal's Rezdiffra (resmetirom) for the treatment of MASH
Ticker: MDGL
Executed On: May 02, 2025 at 02:30 PM EDT -
Checking in with a prescriber of Madrigal's Rezdiffra (resmetirom) for the treatment of MASH
Ticker: MDGL
Executed On: Apr 30, 2025 at 03:30 PM EDT -
Assessing the Two-Year Data from the MAESTRO-NAFLD-1 Trial of Rezdiffra (Resmetirom) in Compensated MASH Cirrhosis from Madrigal Pharmaceuticals
Ticker: MDGL
Executed On: Mar 27, 2025 at 11:00 AM EDT -
Quarterly Survey: MASH/NASH and MDGL's Rezdiffra (resmetirom) January 2025
Ticker: MDGL
Executed On: Jan 22, 2025 at 11:53 AM EST -
Discussing commercial use of Rezdiffra and the topline results of the ESSENCE trial
Ticker: MDGL
Executed On: Dec 03, 2024 at 04:00 PM EST -
A second look: Discussing Rezdiffra and various investigational agents in MASH
Tickers: MDGL, AKRO, ETNB
Executed On: Oct 23, 2024 at 05:00 PM EDT -
Quarterly Survey: MASH/NASH and MDGL's Rezdiffra (resmetirom) October 2024
Ticker: MDGL
Executed On: Oct 18, 2024 at 02:05 PM EDT -
Discussing various investigational agents in MASH and HBV
Tickers: MDGL, AKRO, ETNB
Executed On: Oct 15, 2024 at 11:00 AM EDT -
Quarterly Survey: MASH/NASH and MDGL's Rezdiffra (resmetirom) July 2024
Ticker: MDGL
Executed On: Jul 23, 2024 at 01:35 PM EDT -
Discussing the recent MASH/NASH data presented at the 2024 EASL Congress with a focus on Madrigal's Rezdiffra (resmetirom) and Lilly's tirzepatide
Tickers: MDGL, LLY
Executed On: Jun 28, 2024 at 01:00 PM EDT -
Examining the recent data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) presented at the 2024 EASL Congress
Ticker: MDGL
Executed On: Jun 18, 2024 at 11:00 AM EDT -
Quarterly Survey: MASH/NASH and MDGL's Rezdiffra (resmetirom) April 2024
Ticker: MDGL
Executed On: Apr 18, 2024 at 12:31 PM EDT -
Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Executed On: Dec 05, 2023 at 09:30 AM EST -
Exploring the current treatment landscape and the future direction of available NASH specific drugs with the introduction of GLP-1 agonists
Tickers: MDGL, TERN, ETNB, VKTX
Executed On: Sep 19, 2023 at 10:00 AM EDT -
Comparing 89bio's ENLIVEN data (pegozafermin) to Akero's efruxifermin in NASH
Tickers: ETNB, AKRO, MDGL, ICPT
Executed On: Mar 23, 2023 at 02:30 PM EDT -
A Second Look: Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH
Ticker: MDGL
Executed On: Dec 22, 2022 at 01:00 PM EST -
Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH
Ticker: MDGL
Executed On: Dec 21, 2022 at 03:00 PM EST -
Another view: A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 23, 2022 at 11:00 AM EST -
A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 18, 2022 at 03:00 PM EST -
A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, NVO, MDGL
Executed On: Aug 01, 2022 at 12:00 PM EDT -
Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, MDGL, NVO
Executed On: Jul 13, 2022 at 03:00 PM EDT
Expired Projects (MDGL)
Upcoming & Overdue Catalysts (MDGL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MDGL)
-
Madrigal’s MGL-3196 data released in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) from Phase 2 Clinical Trial
Ticker: MDGL
Occurred on: Dec 06, 2017
Strategic Initiatives (MDGL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
